Clinical characterization of responders to first line (chemo)immunotherapy in platinum-sensitive recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).

• DOI: 10.1200/jco.2023.41.16_suppl.e18017
• Publication Date: 2023-06-04T16:00:42Z
• Authors: Silvia Buriolla; Stefano Cavalieri; Andrea Franza; Simone Rota; Cristiana Bergamini; Salvatore Alfieri; Imperia Nuzzolese; Elena Colombo; Arianna Ottini; Lisa F. Licitra; Carlo Resteghini
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

e18017 Background: RM HNSCC patients (pts) with combined positive score (CPS) ≥1 benefit from immunotherapy (IO), either alone or chemotherapy (CIO). No survival outcome indicators are available. We aim to characterize a real world cohort of pts treated at tertiary cancer center. Methods: analyzed 37 consecutive IO CIO 2016 2022. divided in responders (R) and non (NR) if they achieved an objective response disease stability/progression as best response. For group comparisons, we considered the following clinical variables: age, gender, smoking status, primary site, HPV ECOG performance sites diagnosis (local, regional, distant), time (TTR). categorical variables, compared characteristics 2 groups using chi squared Fisher’s exact tests, appropriate. age used Mann-Whitney test. TTR Cox proportional hazard model. Outcomes (progression free overall survival, PFS OS, respectively) were assessed Kaplan Meier method log-rank Statistical significance was set 0.05. Results: Clinical reported table. Objective rate (ORR) 32%, median DoR 7.5 months (95% confidence interval, CI 2.07-not reached). None examined variables significantly different (R vs NR population, IO- CIO-treated pts). The only major difference between cohorts which longer R non-R (Table). Conclusions: With limits retrospective analysis, observed NR. main predictive (C)IO. Further studies needed define factors response, enhance ORR first-line IO-based treatments. [Table: see text]